IL17A and rheumatoid arthritis: In RA, IL-17 induces synovial fibroblasts and osteoblasts to activate the receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK) signaling pathway associated with osteoclastogenesis, thus resulting in the destruction of bone [6, 7].